8.67

5.25% -0.48

After Hours: 8.67

Verrica Pharmaceuticals Inc (VRCA)

Overview News Price History Option Chain Financials Discussions Forecast

Verrica Pharmaceuticals Inc stock is currently priced at $8.67, with a 24-hour trading volume of 161.88K. It has seen a -5.25% decreased in the last 24 hours and a +22.80% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $9.22 pivot point. If it approaches the $8.40 support level, significant changes may occur.

Previous Close:

$9.15

Open:

$9.25

24h Volume:

161.88K

Market Cap:

$367.78M

Revenue:

$5.12M

Net Income/Loss:

$-67.00M

P/E Ratio:

-16.42

EPS:

-0.5281

Net Cash Flow:

$-38.94M

1W Performance:

+8.38%

1M Performance:

+22.80%

6M Performance:

+147.01%

1Y Performance:

+47.20%

1D Range:

$8.64

$9.28

52W Range:

$2.86

$11.41

Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile

Name

Verrica Pharmaceuticals Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

484-453-3300

Address

10 North High Street, Suite 200, West Chester, PA

Employee

Twitter

Next Earnings Date

2024-06-06

Latest SEC Filings

VRCA's Discussions on Twitter

Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-23	Upgrade	Needham	Hold → Buy
Mar-22-23	Initiated	Jefferies	Buy
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-21	Initiated	RBC Capital Mkts	Outperform
Dec-24-20	Reiterated	H.C. Wainwright	Buy
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy
Jun-24-20	Initiated	Northland Capital	Outperform
Mar-24-20	Initiated	Needham	Buy
Feb-21-19	Initiated	H.C. Wainwright	Buy

View All

Verrica Pharmaceuticals Inc Stock (VRCA) Latest News

VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - ForexTV.com

ForexTV.com

(VRCA) Proactive Strategies - Stock Traders Daily

Stock Traders Daily

Firms look to build on Ycanth success with new indication - The Pharma Letter

The Pharma Letter

Verrica and Torii to conduct global wart treatment trial By Investing.com - Investing.com Nigeria

Investing.com Nigeria

Verrica Pharmaceuticals and Torii Pharmaceutical Expand Collaboration to Combat Common Warts in Global Phase 3 ... - MyChesCo

MyChesCo

Verrica and Torii to conduct global wart treatment trial - Investing.com Australia

Investing.com Australia

Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data

Verrica Pharmaceuticals Inc (VRCA) Revenue 2024

VRCA reported a revenue (TTM) of $5.12 million for the quarter ending December 31, 2023, a -43.27% decline year-over-year.

Verrica Pharmaceuticals Inc (VRCA) Net Income 2024

VRCA net income (TTM) was -$67.00 million for the quarter ending December 31, 2023, a -173.59% decrease year-over-year.

Verrica Pharmaceuticals Inc (VRCA) Cash Flow 2024

VRCA recorded a free cash flow (TTM) of -$38.94 million for the quarter ending December 31, 2023, a -105.46% decrease year-over-year.

Verrica Pharmaceuticals Inc (VRCA) Earnings per Share 2024

VRCA earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a -79.73% decline year-over-year.

Verrica Pharmaceuticals Inc Stock (VRCA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 28 '23	Buy	7.08	126,116	892,901	6,983,408
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 27 '23	Buy	7.20	79,726	574,027	6,857,292
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 26 '23	Buy	6.49	54,652	354,691	6,777,566
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 22 '23	Buy	6.67	250,000	1,667,500	6,722,914
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 21 '23	Buy	6.17	200,000	1,234,000	6,472,914
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 19 '23	Buy	5.36	277,008	1,484,763	6,272,914
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 18 '23	Buy	5.41	456,923	2,471,953	5,995,906
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 15 '23	Buy	5.97	500,000	2,985,000	5,538,983
Hayes Christopher G.	Chief Legal Officer	Nov 15 '23	Sale	2.97	11,558	34,327	123,226
White Ted	President and CEO	Nov 15 '23	Sale	2.97	11,558	34,327	170,090

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is headquartered in West Chester, Pennsylvania.